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Abstract
Background: In the advanced stages of hepatocellular carcinoma (HCC), a tumor thrombus (TT) can form in the
portal or hepatic vein. The management of patients with advanced HCC and a TT extending into the right atrium
(RA) and inferior vena cava (IVC) is extremely difficult and risky.
Case presentation: We report the case of a patient with HCC and a large TT (85 × 45 mm) extending into the RA
through the hepatic vein and IVC, which is very rare. We performed percutaneous microwave ablation of the TT
and the two intrahepatic tumors (maximum diameter, 57 mm). The treatment shrank the tumors, and the patient is
in good condition and has survived for 16 months thus far. A literature review was also performed. This is the first
such case to be treated with percutaneous microwave ablation.
Conclusion: The outcomes in this case suggest that percutaneous ablation is useful for the treatment of TT
extending into the RA and IVC in patients with HCC.
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Background
Hepatocellular carcinoma (HCC) is one of the most
common malignant tumors and the second leading
cause of cancer-related deaths [1]. HCC is a highly pro-
gressive cancer with a high rate of metastasis. Further-
more, tumor thrombus (TT) formation in the portal or
hepatic vein is common in the advanced stages of HCC
[2]. When the tumor thrombus invades the inferior vena
cava (IVC) and right atrium (RA), the prognosis is usu-
ally very poor, since the condition may lead to cardiac
failure or pulmonary embolization [3–5]. Furthermore,
the treatment options at this stage are limited and not
very effective. The general treatment of choice is major
surgery with cardiopulmonary bypass, which is danger-
ous, risky, and expensive. In addition, many patients at
this stage of HCC cannot tolerate such an operation.
We report the case of a patient with HCC associated
with a tumor thrombus extending into the RA that was
treated with percutaneous microwave ablation (MWA).
To our knowledge, this is the first reported case in
which minimally invasive percutaneous ablation was
used to treat an HCC patient with a tumor thrombus
in the RA.
Case presentation
A 73-year-old man, who had been hepatitis B virus
(HBV) positive for around 40 years, was diagnosed with
primary HCC and cirrhosis. He was asymptomatic at the
time, and the tumor was detected during a routine
examination. He was admitted to our hospital, where
a physical examination revealed no abnormality. He
had mild hypertension, which was well controlled. He
had received no treatment for HCC before admission
to our hospital.
Pre-operative computed tomography (CT) revealed
multiple tumor nodules in segments VII and VIII of the
liver (Fig. 1a), with an accompanying tumor thrombus
growing from the accessory hepatic vein, and through
the IVC, and into the RA (Fig. 1b, c, and d). The max-
imal diameters of the tumor nodules and thrombus were
57 and 45 mm, respectively. The length of the thrombus
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was 85 mm. Pre-operative laboratory tests revealed the
following: alpha-fetoprotein (AFP), 266.6 ng/mL; AFP-
L3, 22.7 ng/mL; HBV-DNA, 4.58 × 106 copies/mL;
Eastern Cooperative Oncology Group score, 0; and
Child-Pugh grade, A. His body–mass index was 23.88.
Pre-operative histological examination of the tumor con-
firmed HCC (Fig. 2).
Patients with RA tumor thrombus usually have a poor
prognosis. Sudden death can occur due to right heart
failure or pulmonary embolization. However, our patient
refused surgical treatment. We therefore offered him the
option of percutaneous MWA to which he consented.
Pre-operative transcatheter arterial chemoembolization
(TACE) was performed to label the tumor and
thrombus, so that they could be easily targeted on CT
scans without contrast enhancement. MWA was per-
formed under local anesthesia with 1% lidocaine. The
best puncture path to reach the TT is through the liver
parenchyma, without involving the tumor tissue and im-
portant vessels. Therefore, the left-lateral position was
selected to expose the intersection of the ninth intercos-
tal space and posterior axillary line, which we considered
to be the best puncture point. A 22-G puncture needle
was used to lead the microwave electrode to the target.
The angle and depth of each puncture was calculated
using intraoperative CT scans to ensure that the needle
was in the correct position and direction. After perform-
ing CT and calculating and adjusting the puncture angle
four times, the microwave electrode was successfully ad-
vanced up to the targeted upper part of the TT in the
IVC (Fig. 3a) without any intra-operative complications.
A microwave generator (Vison Medical, Nanjing, P.R.
China), which provided a frequency of 2450 MHz and a
power output of 60 W, was used to ablate the upper part
Fig. 1 Pre-operative CT scanning. a Enhanced CT of the abdominal region showed multiple tumor nodules at the right lobe of the liver and
tumor thrombus in IVC. b Enhanced CT showed an accompanying tumor thrombus in RA (black arrow). c, d Enhanced CT showed tumor
thrombus in IVC and RA (black arrow). CT: computed tomography, RA: right atrium, IVC: inferior vena cava
Fig. 2 Pathology of the thrombus. Hematoxylin-eosin staining of the
tumor thrombus revealed tumor cells consistent with HCC of the pa-
tient (200X). HCC: hepatocellular carcinoma
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of the TT for 6 min. Then, the needle was withdrawn
7 cm until it was back in the liver parenchyma. Sufficient
space was left for the adjustment of the needle heading
the lower part of the TT in the IVC. The lower part of
the thrombus was then ablated using a power output of
70 W for 6 min (Fig. 3b). Afterwards, the basal part
(Fig. 3c) and distal part (Fig. 3d) of the tumor thrombus
in the accessory hepatic vein and the tumor in segment
VII (Fig. 3e) were ablated sequentially. The ablation pro-
cedure was repeated twice to ablate the tumor in seg-
ment VIII (Fig. 3f ) and achieve satisfactory necrosis. The
second and third ablations were performed 8 days apart
within 21 days of the first procedure, with the exact tim-
ing depending on the recovery of liver function. No
complications apart from mild-to-intermediate liver dys-
function were observed, and the patient was discharged
5 days after the last ablation procedure.
Three months later, an intrahepatic tumor recurrence
was detected. TACE and salvage MWA were repeated,
and the tumors were completely ablated. The patient de-
veloped fever and chills on days 7 after this treatment,
and CT revealed a biloma in segment VIII (Fig. 3g). A
drainage tube was inserted. Within 10 days, the fever
was resolved, and the biloma showed significant shrink-
age on CT (Fig. 3h). The patient complained of no dis-
comfort afterwards and was discharged one month after
the salvage ablation. At the time of discharge, his AFP
was 2.66 ng/mL, and magnetic resonance imaging (MRI)
showed necrosis of the tumors in segment VII (Fig. 4a)
and VIII (Fig. 4b) and shrinkage of the tumor thrombus
in the RA (Fig. 4c) and IVC (Fig. 4d).
Enhanced MRI was done during routine follow-up.
With proliferation of the hepatic parenchyma and ab-
sorption of the necrotic tissue, further shrinkage of the
ablated tumors in segment VII (Fig. 5a) and VIII (Fig. 5b)
as well as the tumor thrombus in RA (Fig. 5c) and IVC
(Fig. 5d) was seen 5 months after treatment. The patient
has survived and been followed up for 16 months since
the diagnosis of RA thrombus. Currently, he is alive
without any further recurrence.
Discussion
Only 0.67–4.1% of HCC patients develop a tumor
thrombus extending into the RA [6, 7]. In our patient,
the accessory hepatic vein was invaded by the tumor all
the way up to the RA. This is a very rare condition that
carries a dismal prognosis, as it is associated with a high
risk of systemic metastasis, acute pulmonary embolism,
and heart failure [8–10].
The management of patients with advanced HCC and
a tumor thrombus extending into the RA is difficult and
risky. The prognosis is dismal if only supportive care is
provided (median survival, 5 months) [11]. Surgical ex-
traction of the thrombus and resection of the tumor
Fig. 3 Intra-operative CT scanning and post-operative biloma. a CT scanning showed ablation of the upper part of tumor thrombus in IVC and
RA. b CT scanning showed ablation of the lower part of tumor thrombus in IVC and RA. c CT scanning showed ablation of the basal part of
tumor thrombus in the hepatic vein. d CT scanning showed ablation of the distal part of tumor thrombus in the hepatic vein. d CT scanning
showed ablation of the distal part of tumor thrombus in the hepatic vein. e CT scanning showed ablation of the tumor in segment VII. f CT scan-
ning showed ablation of the tumor in segment VIII. g CT scanning showed biloma which was a fluid collection in the space surrounding the nec-
rotic tissue of the ablation zone at segment VIII (black arrow). h CT scanning showed significant shrinkage of biloma 10 days after drainage (black
arrow). CT: computed tomography, RA: right atrium, IVC: inferior vena cava
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appears to be the only effective treatment option. How-
ever, this is a major open surgery that commonly re-
quires cardiopulmonary bypass [11–16]. Moreover, the
operation involves incising the subcostal arch, RA, IVC,
and all the way down to the hepatic venous root site [4].
Our patient refused surgery and preferred to undergo
minimally invasive treatment. In the past, surgeons
could extract only the tumor thrombus, owing to tech-
nical limitations and the post-operative survival was a
mere 1–9 months (mean, 6 months) [4, 17]. With im-
provements in surgical techniques, it is now possible to
simultaneously resect both the intrahepatic tumor and
the RA tumor thrombus [18, 19]. The mean survival of
patients after this operation, which involves cardiopul-
monary bypass, has been reported to be 20 months
(range, 18 days to 56 months) [14]. These results indi-
cate the benefits of surgical treatment. However, patients
with advanced HCC complicated with tumor thrombus
in the IVC and RA are usually elderly and may not toler-
ate major open surgery to extract the thrombus. More
over, there is a high risk of operative failure and compli-
cations related to general anesthesia in these patients.
The high expense of major operations is also a factor.
TACE does not improve survival in HCC patients with
tumor thrombus [11]. Here, we used TACE to label the
tumor margins and help precisely ablate the thrombus
and tumor masses. TACE and ablation therapy are min-
imally invasive; they do not require systemic anesthesia
and can be tolerated by almost all HCC patients. More-
over, ablation therapy can be repeated to treat large tu-
mors, multiple nodules, and tumor recurrences. This
therapy has become increasingly important in the man-
agement of HCC, and is the treatment of choice in many
other conditions [20]. Therefore, we decided to attempt
ablative therapy in our patient. Since MWA is known
for its larger ablation volumes, shorter duration, and re-
sistance to the heat-sink effect as compared with radio-
frequency ablation, we considered that using MWA
would lessen the number of puncture procedures and
thus reduce the risk of bleeding and ablation failure.
The intra-operative complications in our patient were
mild and transient. No vascular thrombosis related with
the ablation was observed. Abundant blood flow was
present to dissipate the heat generated during ablation,
and thus, the IVC was protected from being damaged by
thermal ablation. The post-operative biloma and bile
track infection in our patient were controlled within
10 days by using drainage and medical care. The patient
has thus far survived for 16 months. He is in a good
condition and is being routinely followed up.
Fig. 4 MRI at 1 month post-operatively. a, b Enhanced MRI of the abdominal region showed ablated tumor area at segment VII and VIII. c, d
Coronal sequence of enhanced MRI of the abdominal region showed the shrinkage of the tumor thrombus in IVC and RA (black arrow). MRI: mag-
netic resonance imaging, RA: right atrium, IVC: inferior vena cava
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A potential severe complication of our treatment is pul-
monary embolism due to dislodgement of the ablated
thrombus. However, this complication was not observed in
our patient and has not yet been reported in the literature.
To our knowledge, this is the first report of the use of
percutaneous ablation therapy for the management of an
HCC patient with a tumor thrombus in the IVC and
RA. The results in this patient indicate that this treat-
ment may have comparable efficacy to conventional
open surgery with less local trauma and without the
need for general anesthesia.
Conclusions
Percutaneous ablation therapy might represent a useful and
promising therapeutic modality for HCC patients with
tumor extension into the RA and IVC, including patients
with advanced tumors and older patients. Large-scale clin-
ical trials of HCC patients with RA/IVC tumor thrombosis
treated with percutaneous ablation are ongoing in China.
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